A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
Status unconfirmed · Phase 1
Conditions studied: Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
In brief
This is a phase 1, Open-label, multicenter Dose Escalation study of BTP-114, a novel platinum product, in patients with advanced solid tumors and BRCA or other DNA repair mutation. This clinical study is comprised of 2 sequential parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The purpose of this study is to evaluate the safety, pharmacokinetics and the anti-cancer activity of BTP-114.
Key facts
- Study ID
- NCT02950064
- Run by
- Placon Therapeutics
- People needed
- 95
- Starts
- 2016-09-01
- Expected to finish
- 2020-08-01
- Last updated by the study team
- 2019-01-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Placon Therapeutics Clinical Trial Site — Sarasota, Florida, United States
- Placon Therapeutics Clinical Trial Site — Boston, Massachusetts, United States
- Placon Therapeutics Clinical Trial Site — Boston, Massachusetts, United States
- Placon Therapeutics Clinical Trial Site — St Louis, Missouri, United States
- Placon Therapeutics Clinical Trial Site — Cleveland, Ohio, United States
- Placon Therapeutics Clinical Trial Site — Oklahoma City, Oklahoma, United States
- Placon Therapeutics Clinical Trial Site — Nashville, Tennessee, United States
- Placon Therapeutics Clinical Trial Site — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.